In a report issued on June 28, Jason Kolbert from Dawson James maintained a Buy rating on Bluejay Diagnostics (BJDX – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $1.05, close to its 52-week low of $0.82.
According to TipRanks.com, Kolbert is a 1-star analyst with an average return of -1.9% and a 35.1% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Citius Pharmaceuticals.
Bluejay Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $6.25 and a one-year low of $0.82. Currently, Bluejay Diagnostics has an average volume of 940.4K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BJDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.
Read More on BJDX:
- Micron Stock: Extend Your Timeline and Stay Invested
- Bed Bath & Beyond’s Business seems Beyond Repair, for Now
- ALK spotlights the impact of respiratory allergies on children at EAACI Congress
- Kepler Capital Sticks to Its Sell Rating for Uniper SE (UNPRF)
- Uniper SE (UNPRF) Gets a Buy Rating from J.P. Morgan
